TScan Therapeutics, Inc. filings document the regulatory record for a clinical-stage biotechnology company developing TCR-engineered T cell therapies. Its 8-K filings furnish operating results, corporate presentations, and pipeline disclosures tied to TSC-101, the ALLOHA heme program, CD45-targeted candidates, solid-tumor research, and autoimmunity target discovery.
The company’s filings also cover governance and capital-structure matters, including officer role changes, compensation and retention arrangements, costs associated with portfolio prioritization, and proxy proposals for director elections, auditor ratification, and authorized common stock. The records identify TCRX voting common stock as listed on the Nasdaq Global Market.
On October 1, 2026, TScan Therapeutics, Inc. CEO Gavin MacBeath received an award of 1,000,000 shares of Voting Common Stock in the form of restricted stock units (RSUs). His reported direct holdings after the award were 1,049,767 shares. Twenty-five percent of the RSUs vest on September 30, 2028; the remaining 75% vest on the earlier of reporting of completion of the TSC-101 pivotal trial or September 30, 2030, subject to continued service and the terms of the equity incentive plan and award agreement.
TScan Therapeutics, Inc. (TCRX) Chief Legal and Strategy Officer Zoran Zdraveski received an award reported as 300,000 shares of Voting Common Stock on October 1, 2026. His reported direct holdings following the transaction were 304,716 shares.
The award terms provide that 25% of the RSUs vest on September 30, 2028; the remaining 75% vest on the earlier of reported completion of the pivotal TSC-101 trial or September 30, 2030, subject to continued service through the applicable vesting dates and the plan and award agreement terms.
TScan Therapeutics, Inc. (TCRX) entered separation agreements with Jason A. Amello, its Chief Financial Officer, and Chrystal Louis, M.D., MPH, its Chief Medical Officer, following a previously announced strategic reorganization. The agreements provide that each executive’s employment will end on the earlier of November 1, 2026, or the date the executive begins other employment, consulting, or paid board service. Base salary and applicable employee benefits continue until that separation date.
Each executive remains entitled to previously disclosed termination-related payments and benefits. Under the 2025 Retention Program, Amello may receive a $85,000 lump-sum cash award and Louis may receive a $125,000 lump-sum cash award, each payable only if a specified company milestone is achieved before that executive’s separation date.
TScan Therapeutics, Inc. (TCRX) is the issuer in a Schedule 13G reporting 3,453,388 shares of voting common stock, or 5.4%, as beneficially owned by Readout Capital, LP, Readout Capital GP, LLC, and Matthew Smith. Each reports shared voting and dispositive power over the shares, with no sole voting or dispositive power reported.
The shares are held directly by Readout Capital Master Fund, LP and the Sub-Advised Funds. Readout Capital, LP is their investment manager, Readout Capital GP, LLC is the firm's general partner, and Smith is the GP's managing member. The percentage calculation uses 63,502,667 shares outstanding as of August 7, 2026.
TScan Therapeutics, Inc. (TCRX) approved a key employee retention program on September 8, 2026 that grants significant cash and equity incentives to selected employees, including Chief Executive Officer Gavin MacBeath, Ph.D., and Chief Legal and Strategy Officer Zoran Zdraveski, JD, Ph.D.
Under this program, Dr. MacBeath is eligible for a $822,000 cash award and 2,400,000 RSUs, and Dr. Zdraveski for a $416,000 cash award and 1,050,000 RSUs. Portions of the cash awards are scheduled to be paid in November 2026 and February 2027, with the remainder tied to a clinical milestone for the company’s in vivo solid tumor program. The RSUs are to be granted under the Amended and Restated 2021 Equity Incentive Plan, with one-third vesting upon achievement of a financing milestone and the remaining two-thirds vesting in equal installments on the first and second anniversaries of that financing milestone, subject to continued service and plan terms.
TScan Therapeutics, Inc. (TCRX) is executing a major strategic reorganization to prioritize preclinical development of its in vivo solid tumor program and has paused further enrollment in its Phase 3 ALLOHA-2™ study of TSC-101 for heme malignancies due to capital constraints. As part of this shift, the company is eliminating its internal manufacturing organization, significantly reducing its research footprint, and implementing a workforce reduction of approximately 75%, which is expected to generate cumulative cost savings of $55.0 million through the end of 2027. TScan expects to incur about $4.1 million in employee-related charges, largely future cash costs, and believes its cash, cash equivalents and marketable securities as of June 30, 2026 will fund operations into the fourth quarter of 2027.
The company reported encouraging Phase 1 ALLOHA™ data for TSC-101: all 13/13 Cohort C patients currently tracked show complete donor chimerism, with tolerability consistent with post-transplant expectations. Despite this, the heme malignancy and autoimmunity programs are being paused while TScan seeks strategic partnerships. Separately, TScan received a Nasdaq notice that its stock failed to meet the $1.00 Minimum Bid Price Rule, triggering an initial 180-day compliance period to February 23, 2027. The CFO and CMO roles were terminated without cause in connection with the reorganization, and CEO Gavin MacBeath has assumed principal financial and accounting officer duties.
TScan Therapeutics, Inc. (TCRX) reports that Amgen has elected to terminate in its entirety their Research Collaboration and License Agreement, which focused on using TScan’s target discovery platform to identify T‑cell antigens in Crohn’s disease. Amgen is exercising a contractual right to terminate with 90 days’ prior written notice, making the termination effective November 10, 2026, and TScan will incur no early termination penalty. TScan had previously received a $30.0 million non‑refundable upfront payment in 2023; the agreement also contemplated more than $500 million in success‑based milestones and tiered single‑digit royalties on future product sales. After termination, TScan does not expect future milestone or royalty payments from this collaboration unless Amgen or its affiliates or sublicensees continue to exploit product candidates, in which case applicable milestones and royalties would survive under the agreement’s terms.
Lynx1 Capital Management LP and Weston Nichols report beneficial ownership of TScan Therapeutics, Inc. Voting Common Stock. Through Lynx1 Master Fund LP, they jointly report 20,519,148 shares of Voting Common Stock, representing 13.1% of the class, based on 61,074,229 shares outstanding as of May 1, 2026. All reported shares are held with shared voting and dispositive power, and the Lynx1 Fund has the right to receive dividends and sale proceeds from these shares. The filing states it should not be construed as an admission that any Reporting Person is the beneficial owner for all purposes.
Biotechnology Value Fund and affiliates report significant ownership in TScan Therapeutics, Inc. (TCRX). As of June 30, 2026, BVF, BVF2, Trading Fund OS and related entities and a managed account beneficially owned an aggregate of 6,417,831 shares of Voting Common Stock, representing approximately 9.99% of the outstanding shares. This includes Pre-Funded Warrants exercisable for 1,219,288 shares at an exercise price of $0.0001 per share, which do not expire and are subject to a 9.99% beneficial ownership blocker that currently limits exercisability to 853,541 underlying shares. Individually, BVF holds 3,649,002 shares (about 5.7%) and BVF2 holds 2,662,237 shares (about 4.2%), with various BVF general partners and management entities deemed to share voting and dispositive power over these positions.
TScan Therapeutics, Inc. reported continued operating losses and liquidity pressure for the quarter ended June 30, 2026. Collaboration and license revenue was $1.1 million, down from $3.1 million a year earlier, reflecting timing of work under its Amgen collaboration. Research and development expense decreased to $23.4 million from $32.6 million as the company reduced lab spend and headcount after prioritizing its hematologic malignancy programs. General and administrative expense declined modestly to $8.1 million.
Net loss for the quarter was $30.4 million, compared with $37.0 million in the prior-year period. As of June 30, 2026, TScan held $100.2 million in cash and cash equivalents (plus $5.0 million restricted cash) and had an accumulated deficit of $563.9 million. Management states that existing cash is expected to fund operations into the second quarter of 2027, but concludes that substantial doubt exists about the company’s ability to continue as a going concern for 12 months after the financial statements’ issuance.
The company has a $32.5 million term loan outstanding under a Silicon Valley Bank facility, bearing interest at a minimum of 7.00% and subject to a 5% final payment fee. Because TScan did not meet a specified financial milestone by June 30, 2026, interest-only payments will end on September 30, 2026 and principal amortization will accelerate, with the loan now scheduled to mature on September 1, 2028.